Accession Number:



A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence

Descriptive Note:

Technical Report,01 Jul 2016,30 Jun 2017

Corporate Author:

Upstate Medical University Syracuse United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Our traumahemorrhagic shock THS injury model was highly effective at causing acute respiratory distress syndrome ARDS in all Control groups. However, TRB-N0224 treatment, although it lowered both plasma and bronchoalveolar lavage BALF IL-6 levels, resulted in no significant improvement in clinical outcome, in the form of improve lung function i.e lung compliance or PaO2FiO2 ratio or histopathology. We postulate that there were two problems with the study 1 the stress of the gavage was an additional trauma in an already severe THS model and 2 the THS model causes severe damage to the gut, which significantly reducedTRB-N0224 adsorption. To solve this problem we have requested a one-year no-cost extension to use an intravenous formulation of TRB-N0224 that, if our postulate is correct, will solve both of our problems. As a secondary solution to our problem if the IV formulation of TRBN0224is not effective in the THS model we will try in our rat cecal ligation and punctureCLP model. This will determine if TRB-N0224 is effective for trauma andor sepsis.

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology

Distribution Statement: